BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 25156038)

  • 1. Comparison of methods for evaluating radiolabelled Annexin A5 uptake in pre-clinical PET oncological studies.
    Grafström J; Stone-Elander S
    Nucl Med Biol; 2014; 41(10):793-800. PubMed ID: 25156038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-specifically 11C-labeled Sel-tagged annexin A5 and a size-matched control for dynamic in vivo PET imaging of protein distribution in tissues prior to and after induced cell death.
    Cheng Q; Lu L; Grafström J; Olofsson MH; Thorell JO; Samén E; Johansson K; Ahlzén HS; Linder S; Arnér ES; Stone-Elander S
    Biochim Biophys Acta; 2013 Mar; 1830(3):2562-73. PubMed ID: 23262140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
    Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining [11C]-AnxA5 PET imaging with serum biomarkers for improved detection in live mice of modest cell death in human solid tumor xenografts.
    Cheng Q; Lu L; Grafström J; Olofsson MH; Thorell JO; Samén E; Johansson K; Ahlzén HS; Stone-Elander S; Linder S; Arnér ES;
    PLoS One; 2012; 7(8):e42151. PubMed ID: 22870292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms.
    Kitagawa Y; Sadato N; Azuma H; Ogasawara T; Yoshida M; Ishii Y; Yonekura Y
    J Nucl Med; 1999 Jul; 40(7):1132-7. PubMed ID: 10405132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer.
    Schinagl DA; Vogel WV; Hoffmann AL; van Dalen JA; Oyen WJ; Kaanders JH
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1282-9. PubMed ID: 17967318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of FDG-PET/CT on the management of head and neck tumours: the radiotherapist's perspective.
    Dietl B; Marienhagen J; Kühnel T; Schreyer A; Kölbl O
    Oral Oncol; 2008 May; 44(5):504-8. PubMed ID: 17826307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical values for abnormal ¹⁸F-FDG uptake in the head and neck region of patients with head and neck squamous cell carcinoma.
    Lee HS; Kim JS; Roh JL; Choi SH; Nam SY; Kim SY
    Eur J Radiol; 2014 Aug; 83(8):1455-60. PubMed ID: 24929443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in (18)F-fluorothymidine and (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy.
    Hoshikawa H; Mori T; Kishino T; Yamamoto Y; Inamoto R; Akiyama K; Mori N; Nishiyama Y
    Ann Nucl Med; 2013 May; 27(4):363-70. PubMed ID: 23378102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio.
    Lehtiö K; Oikonen V; Nyman S; Grönroos T; Roivainen A; Eskola O; Minn H
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):101-8. PubMed ID: 12483416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of [18F] fluoro-2-deoxy-D-glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection.
    Inokuchi H; Kodaira T; Tachibana H; Nakamura T; Tomita N; Nakahara R; Takada A; Mizoguchi N; Tamaki T; Fuwa N
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):747-55. PubMed ID: 20434274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
    Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of different methods of 18F-FDG-PET target volume delineation in the radiotherapy of head and neck cancer.
    Greco C; Nehmeh SA; Schöder H; Gönen M; Raphael B; Stambuk HE; Humm JL; Larson SM; Lee NY
    Am J Clin Oncol; 2008 Oct; 31(5):439-45. PubMed ID: 18838879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential role of non-FDG-PET in the management of head and neck cancer.
    Heuveling DA; de Bree R; van Dongen GA
    Oral Oncol; 2011 Jan; 47(1):2-7. PubMed ID: 21109481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies.
    Yamamoto Y; Wong TZ; Turkington TG; Hawk TC; Coleman RE
    Radiology; 2007 Jul; 244(1):263-72. PubMed ID: 17495174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal PET imaging of doxorubicin-induced cell death with 18F-Annexin V.
    Hu S; Kiesewetter DO; Zhu L; Guo N; Gao H; Liu G; Hida N; Lang L; Niu G; Chen X
    Mol Imaging Biol; 2012 Dec; 14(6):762-70. PubMed ID: 22392643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
    J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.
    Menda Y; Graham MM
    Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of FDG-PET/CT fused imaging on tumor volume assessment of head-and-neck squamous cell carcinoma.
    Tikkakoski T
    Acta Radiol; 2008 Jul; 49(6):615-6. PubMed ID: 18568550
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.